medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2016, Number 2

<< Back Next >>

Acta Pediatr Mex 2016; 37 (2)

Risk factors associated with the metabolic bone disease of prematurity in neonatal intensive care unit of reference

Ríos-Moreno MP, Salinas-López MP, Pérez-Ornelas NB, Barajas-Serrano TL, Barrera-de León JC

Language: Spanish
References: 35
Page: 69-78
PDF size: 618.49 Kb.


ABSTRACT

Introduction: Metabolic bone disease of prematurity (MBD) results from bone demineralization. There are factors that must be monitored in order to early diagnosis and treatment.
Aim:This study was conducted to determine risk factors associated with the metabolic bone disease of prematurity.
Method: A Cross-sectional study was conducted in October/2011 to October/2012. We included 120 preterm infants with gestational age ‹37 weeks, birth weight ≤ 1500 grams and postnatal age ≥ 21 days. Diagnosis: hypophosphatemia (‹ 3.5 mg/dL), normocalcemia (8.5-10 mg/ dL) or hypocalcemia (‹ 8.5 mg/dL) increase in alkaline phosphatase (› 900 IU/L). We calculated odds ratio (OR). Data were analysed by Student t-test and the chi-square test.
Results: Metabolic bone disease of prematurity was diagnosed in 58 (48%) patients, weight 1067 ± 216 grams, gestational age 28 ± 1.6 weeks, postnatal age 41 ± 15.5 days. Gender male 32 (55%). The risk factors associated with the disease were: birth weight ≤ 1,000 grams OR 4.64 (2.13-10.10), moderate or severe bronchopulmonary dysplasia 3.13 (1.44-6.81), sepsis events ≥ three OR 3.43 (1.62-7.28), prolonged sedation OR 4.09 (1.06-15.73), prolonged corticoid OR 9.54 (2.06-44.16).
Conclusions: Is probably the birth weight less than 1,000 grams, moderate or severe bronchopulmonary dysplasia, three or more events of sepsis and prolonged sedation and corticoid were significant risk factors for MBD.


REFERENCES

  1. Unidad Neonatal. Departamento de Pediatría. Unidad Neonatal. Hospital Británico. Osteopenia del prematuro. Arch Pediatr Urug. 2006;77:290-2.

  2. Litmanovitz I, Dolfin T, Friedland O, ArnonS, Regev R, Shainkin-Kestenbaum R, et al. Early Physical Activity Intervention Prevents Decrease of Bone Strength in Very Low Birth Weight Infants. Pediatrics. 2003;112:15-9.

  3. Lewis PR. Disorders of Calcium and Phosphorus Metabolism. In: Taeusch HW. Ballard RA, Gleason CA, eds. Avery´s Diseases of the Newborn, 8a ed. Philadelphia, EUA: Hartcourt, 2005, pp.1364-6.

  4. Huttner KM. Enfermedad ósea metabólica de la prematuridad. In: Cloherty JP, Eichenwald EC, Stark AR, eds. Manual de cuidados neonatales, 4a ed. Barcelona, España: Masson, 2005, pp. 682-5.

  5. Narbona E, García D, García JL, Galdó G, Maldonado J. Cambios en la mineralización ósea de los niños nacidos a término y prematuros en los primeros cuatro meses de vida. Acta Pediatr Esp. 1995;53:641-47.

  6. Harrison C, Gibson A. Osteopenia in preterm infants. Arch Dis Child Fetal Neonatal Ed 2013;98:F272-F275.

  7. Yeşiltepe MG, Kırmızıbekmez H, Özsu E, Er I, Hatun S. Metabolic Bone Disease of Prematurity: Report of Four Cases. J Clin Res Pediatr Endocrinol. 2014;6(2):111–115.

  8. King-woon SO, Pak-cheung NG. Treatment and prevention of neonatal osteopenia. Current Paediatrics. 2005;15:106- 13.

  9. Taeusch HW, Yogman MW. Follow-up management of the high-risk infant. Little, Brown. Boston, EUA, 1987. pp. 83-97.

  10. Tsang R. Calcio, fósforo y magnesio. In: Solá A, Rogido M, eds. Cuidados especiales del feto y el recién nacido, Buenos Aires, Argentina: Científica Interamericana, 2001, pp. 396-423.

  11. Rohana J, Hasmawati J, Zulkifli SZ. Risk factors associated with low bone mineral content in very low birth weight infants. Singapore Med J. 2007;48:191-94.

  12. Ministerio de Salud de Chile. Guías Nacionales de Neonatología. Enfermedad óseo-metabólica del prematuro. Comisión Nacional de Seguimiento de Prematuros. Santiago, Chile, 2005. pp. 119-23.

  13. Taeusch W, Avery M. Osteopenia de los prematuros. In: Avery M, eds. Compendio de neonatología, 7a ed. Madrid, España: Harcourt, 2001, pp. 437-8.

  14. Bertocci LA, Mize CE, Uauy R. Muscle phosphorus energy state in very-low-birth-weight infants: effectof exercise. Am J Physiol. 1992;262:289-94.

  15. Vachharajani AJ, Mathur AM, Rao R. Metabolic Bone Disease of Prematurity. Neo Reviews. 2009;10:402-11.

  16. Llanos MA, Mena NP, Uauy DR. Tendencias actuales en la nutrición del recién nacido prematuro. Rev Chil Pediatr. 2004;75:107-21.

  17. Zerpa MY, Paoli VM. Actualización diagnóstico-terapéutica del raquitismo. Revisión. Rev Venez Endocrinol Metab. 2004;2:2-9.

  18. Nolla J. Enfermedades óseas. Sociedad Española de Reumatología. Masson. Barcelona, España, 1997. pp. 21-23.

  19. Fewtrell MS. Does early nutrition program later bone health in preterm infants? Am J Clin Nutr. 2011;94(6 Suppl):1870S-1873S.

  20. Wilson SJ, Román NA, Beca IJ, Cortes EJ, Amaral PH, Morales KB, et al. Osteopenia de niños nacidos antes de término: Evaluación mediante densitometría ósea. Rev Chil Pediatr.1993;64:89-93.

  21. Rubinacci A, Moro EG, Boehm G, Terlizzi F, Moro GL, Cadossi R. Quantitative ultrasound for the assessment of osteopenia in preterm infants. Eur J Endocrinol. 2003;149:307-15.

  22. Hernández CM, Talesnik GE, García BC, Reyes GM. Enfrentamiento clínico de la osteoporosis en el niño. Rev Chil Pediatr. 2003;74:568-77.

  23. Backstrom MC, Kouri T, Kuusela AL. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Pediatr. 2000;89:867-73.

  24. Tinnion RJ1, Embleton ND. How to use... alkaline phosphatase in neonatology. Arch Dis Child Educ Pract Ed. 2012;97:157-63.

  25. Kelly A, Kovatach K, Garber S. Metabolic Bone Disease Screening Practices Among U.S. Neonatologists Clin Pediatr. 2014;53:1077-1083.

  26. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-9.

  27. Mitchell SM, Rogers SP, Hicks PD, Hawthorne KM, Parker BR, Abrams SA. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr. 2009;29:9-47.

  28. Román NA, Wilson SJ, Beca IJ, Cortés EJ, Polette BV, Espindola AAM. Fosfatasas alcalinas en el estudio de la osteopenia del prematuro. Rev Chil Pediatr. 1993;64:359-63.

  29. Tapia-Rombo CA, Villalobos-Granja KP, Ramírez-Pérez J, Uscanga-Carrasco H, Robles-Espinosa LA. Aparición de la osteopenia en recién nacidos de pretérmino en un servicio de neonatología. Bol Med Hosp Infant Mex. 2013;70(6):432-440.

  30. Abrams SA; Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics. 2013;131(5):e1676-83.

  31. Bozzetti V, Tagliabue P. Metabolic Bone Disease in preterm newborn: an update on nutritional issues. Ital J Pediatr. 2009;35:20.

  32. Lucas A, Brooke OG, Baker BA, Bishop N, Morley R. High alkaline phosphatase activity and growth in preterm neonates. Arch Dis Child. 1989;64:902-9.

  33. Rustico SE, Calabria AC, Garber SJ. Metabolic bone disease of prematurity. Journal of Clinical & Translational Endocrinology. 2014;85e91.

  34. Hitrova S, Slancheva B, Popivanova A, Vakrilova L, Pramatarova T, Emilova Z, et al. Osteopenia of prematurity- -prophylaxis, diagnostics and treatment. Akush Ginekol (Sofiia). 2012;51(7):24-30.

  35. Lothe A, Sinn J, Stone M. Metabolic bone disease of prematurity and secondary hyperparathyroidism. Journal of Paediatrics and Child Health. 2011;550–553.




2020     |     www.medigraphic.com